High risk of recurrence target CD20 – rituximab

[lak1]

I think this may be one for Catherine to ask one of the scientific board members.

I read an abstract Molecular Therapy,(21 February 2012) doi:101038/mt.2012.27

Rituximab was given to nine patients at high risk melanoma recurrence( they were stage IV but rendered disease free via surgery chemo and or radiation). A small group of patients had a good outocome 6 /9 alive 5 recurrence free 2 years after the therapy ended.

For those ineligible for any trials would this be something we might wish to consider. Would having had ipilimumab 2 years ago be a problem- would ipilimumab make this more risky ?

[Catherine Poole]

Gosh, I don’t like what I read about this therapy: http://www.nlm.nih.gov/medlineplus/druginfo/meds/a607038.html

But is there a trial with this going on now? Sounds like very small numbers.

[Author]

Posts